Coherus Biosciences (CHRS) Physician Survey Offers Promising Data - Baird
Tweet Send to a Friend
Baird analyst Michael Ulz reiterated an Outperform rating and $28.00 price target on Coherus Biosciences (NASDAQ: CHRS) after surveying 35 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
